Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,745

Document Document Title
WO/2024/050725A1
The application discloses methods useful for the synthesis of certain 2, 3, 5, 6-alkyl-1, 4-benzoquinone compounds, including 2, 3, 5-trimethyl-6-nonylcyclohexa-2, 5-diene-1, 4-dione, and synthetic intermediates for the production thereof.  
WO/2024/054871A1
The application discloses methods useful for the synthesis of certain 2,3,5,6-alkyl-1,4-benzoquinone compounds, including 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione, and synthetic intermediates for the production thereof.  
WO/2024/003428A1
The present invention relates to quinone-derived compounds with leishmanicidal activity and to the use of same in the pharmaceutical industry, specifically in the field of parasitic diseases. The invention relates specifically to a compo...  
WO/2023/218995A1
The purpose of the present disclosure is to provide a novel adsorption agent. The present disclosure includes a compound represented by formula (3). (In formula (3), each occurrence of R1 independently represents a hydrogen atom or an ...  
WO/2023/120552A1
The present specification discloses a reduced coenzyme Q10 product which does not require the formulation of reduced coenzyme Q10 and in which the oxidation of reduced coenzyme Q10 is suppressed. Also, the present specification discloses...  
WO/2023/120558A1
The present specification discloses a method for storing reduced coenzyme Q10 (QH), the method being capable of suppressing oxidation. The first embodiment of the present invention relates to a method for storing QH, the method includi...  
WO/2023/120557A1
The present description discloses a packaged body of reduced coenzyme Q10, which eliminates the need for formulating the reduced coenzyme Q10 into a preparation, does not undergo the oxidation of the reduced coenzyme Q10 and can be store...  
WO/2023/120555A1
The present description discloses a favorable means for suppressing oxidation of reduced coenzyme Q10 (QH) without requiring formulation of QH. At least one embodiment of the present invention relates to a method for storing reduced co...  
WO/2023/120553A1
The present description discloses a preferred means for preventing the oxidation of reduced coenzyme Q10 (QH) without requiring the formulation of QH into a preparation. One or more embodiments of the present invention relates to: a me...  
WO/2023/102759A1
The present invention relates to a composition comprising 2-amylenyl-anthraquinones and to its preparation method. The composition can be used for producing a composition comprising 2-amylanthraquinone isomers with specific molar ratio.  
WO/2023/100152A1
The present disclosure provides compositions containing glutathione, coenzyme Q10 (CoQ10), pyrroloquinoline quinone, and/or iron binding glycoproteins. Formulations comprising the compositions described herein are also provided. Methods ...  
WO/2023/099154A1
Anthracene-9,10-dione derivatives are capable of producing bleach-active species under irradiation of visible light, which lead to an increase of the bleaching power during the washing of textiles.  
WO/2023/096111A1
The present application relates to a novel quinizarine derivative, wherein the quinizarine derivative has a bromodomain extra-terminal (BET) protein inhibition ability, and thus can be used in a pharmaceutical composition for preventing ...  
WO/2023/090313A1
The purpose of the present invention is to newly discover a transient receptor potential ankyrin 1 (TRPA1) agonist that exhibits an action for increasing the amount of food ingested, to provide a novel agonist of TRPA1, or to provide a n...  
WO/2023/081725A1
Provided herein are compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided a...  
WO/2023/073080A1
The present invention relates to a process for preparing aromatic acyl derivatives of formula (I) using methanesulfonic acid. The invention further relates to methods for preparing biological active ingredients, such as paracetamol.  
WO/2023/059640A1
The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (I), including pharmaceutically acceptable salts th...  
WO/2023/031841A1
The present disclosure relates to a novel process for the synthesis of stereospecific compounds of Vitamin K2 group in general and Vitamin K2-7, in particular. It also discloses novel intermediates useful in the synthesis of stereospecif...  
WO/2023/011668A1
Disclosed in the present invention are a perinaphthenone compound and the use thereof. The compound can bind to E3 ubiquitin ligase tripartite motif 25 (TRIM25), thereby facilitating the recognition of TRIM25 to a pathogen and inducing p...  
WO/2023/009610A1
The application discloses methods useful for the synthesis of racemic, scalemic, and chiral alpha-tocotrienol quinone, including synthetic intermediates and methods for making said synthetic intermediates.  
WO/2023/285509A1
The present invention relates to a process for the preparation of a compound having formula (I) wherein R is selected from the group consisting of: halogen, (C1-C6)alkoxy, (C1-C6)alkyl, halo(C1-C6)alkyl, and halo(C1-C6)alkoxy, said proce...  
WO/2022/261347A1
The disclosure provides various new and existing compounds for use alone or as formulated in a composition (e.g., medicaments) and related methods and uses for treating, preventing, inhibiting, ameliorating or delaying the onset of a dis...  
WO/2022/257994A1
Disclosed are a cryptotanshinone derivative, a preparation method therefor and an application thereof in anti-myocardial fibrosis. The new cryptotanshinone derivative has a structural formula of (I). Preliminary experimental results show...  
WO/2022/254047A1
The invention generally relates to emodin derivatives of general structure (I), to pharmaceutical compositions comprising same and to their uses in medicine, especially in the treatment of bacterial or viral infections. The invention fur...  
WO/2022/233417A1
The present invention relates to the manufacture of benzoquinones, in particular to the manufacture of a potassium salt of a benzoquinone, such as 2,5-dihydroxy-l,4-benzoquinone di-potassium salt. The potassium salt of a benzoquinone is ...  
WO/2022/216359A1
An analytical method is disclosed that includes the steps of: providing a sample potentially containing a chiral analyte that can exist in stereoisomeric forms; providing a probe selected from the group consisting of quinones and analogs...  
WO/2022/204811A1
The present application relates to water-soluble formulations. More specifically, the present application relates to formulations comprising at least one of Coenzyme-Q10 and an ashwagandha root extract and a solubilizing agent. More spec...  
WO/2022/202213A1
The purpose of the present disclosure is to provide a method for efficiently obtaining reduced coenzyme Q10 crystals of Form II that is a stable crystal form, particularly reduced coenzyme Q10 crystals of Form II having excellent oxidati...  
WO/2022/202215A1
The purpose of the present invention is to provide a method which is for producing form-II type reduced coenzyme Q10 crystals or a crystalline solid thereof, and which enables stable production of form-II type reduced coenzyme Q10 crysta...  
WO/2022/202214A1
The purpose of the present disclosure is to provide a production method that is for reduced coenzyme Q10 Form-II type crystals or a crystalline solid thereof and that enables excellent filtering ability of a slurry containing reduced coe...  
WO/2022/192633A1
The present disclosure provides for a pharmaceutical composition comprising ubiquinone-5 (UB5) and method of use thereof. The present disclosure relates to ubiquinone-5 used as an anesthetic, sedative agent, hypnotic agent, or combinatio...  
WO/2022/188233A1
The present invention relates to the use of a TMPD-TXBQ cocrystal material in laser ignition. TMPD-TXBQ of the present invention can be applied to the laser ignition of an energetic material as a light-controlled detonating agent. The TM...  
WO/2022/184904A1
The present invention relates to a method for the preparation of a compound having formula (I) wherein: • R1, R2, R3, and R4 are in particular H or halogen, • R5 is in particular (C1-C6)alkyl, • R6 is a group of formula -CH=CH2 or ...  
WO/2022/184938A1
A compound of formula (I): (I) wherein n is an integer between 0 and 10; Y is hydrogen, halide, mesylate, tosylate, ester, -SPh, -SO2Ph, hydroxyl or protected hydroxyl; with the proviso that if n = 0 or 1, Y is not hydrogen.  
WO/2022/144920A1
The present invention discloses Atovaquone prodrugs, process for the preparation of said prodrugs and pharmaceutical compositions comprising Atovaquone prodrugs. Atovaquone prodrugs of the present invention can be used alone, or co-admin...  
WO/2022/129185A1
The present invention generally relates to the production of vanillin and related compounds (such as aromatic carboxylic acids, quinones, etc.) involving the oxidative cleavage of aromatic compounds (such as lignin, lignols, cinnamic aci...  
WO/2022/107095A1
Disclosed are methods of treating pain, such as headaches, comprising administering an ergotamine and thymoquinone, wherein the ergotamine is selected from the group consisting of BOL-148, lysergic acid diethylamide (LSD), and lysergic a...  
WO/2022/104763A1
Provided process for cyclization of 2- (4' -alkylbenzoyl) benzoic acid to corresponding 2-alkylanthraquinone in the presence of an improved zeolite catalyst, which is capable of increasing the conversion of 2- (4' -alkylbenzoyl) benzoic ...  
WO/2022/091123A1
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula (I) to (IV) for the treatment of cancer.  
WO/2022/057603A1
The present invention relates to a method for extracting coenzyme Q10 from a fermentation broth of coenzyme Q10, comprising subjecting the fermentation broth of coenzyme Q10 to pre-processing, leaching, crystallization, dissolution, chro...  
WO/2022/051291A2
Novel compounds which inhibit DYRK1A activity comprise thymoquinone derivatives including a pair of substituted or unsubstituted six-membered carbon rings selected from phenyl and cyclohexadiene linked by an alkyl or alkenyl linker. Each...  
WO/2022/015181A1
The invention relates to a method and intermediate compounds for the preparation of menaquinone MK-7. The method for the preparation of menaquinone MK-7 is characterized in that, it comprises coupling of a compound of formula (11) with a...  
WO/2021/238947A1
Disclosed is a method for preparing a quinone compound. The present invention provides a method for preparing a quinone compound, the method comprising the following step: in the presence of a base, subjecting a compound as shown in form...  
WO/2021/234078A1
The present invention relates to the photooxidation of 2,3,6-trimethyl- phenol to yield 2,3,5-trimethylbenzoquinone using methylene blue as photo- sensitizer in a solvent mixture of water and alcohols using light of the high wave- length...  
WO/2021/234077A1
The present invention relates to the photooxidation of 2,3,5-trimethyl- phenol to yield 2,3,5-trimethylbenzoquinone using methylene blue as photo- sensitizer in a solvent mixture of water and alcohols using light of the high wavelength r...  
WO/2021/234080A1
The present invention relates to the photooxidation of phenolic compounds to the respective quinoid compounds using methylene blue as photosensitizer in a solvent mixture of water and alcohols using light of the high wavelength range of ...  
WO/2021/232543A1
Disclosed is a method for separating coenzyme Q10 by means of using a supercritical fluid chromatography system, the method comprising: (1) starting a supercritical fluid chromatography system and setting system parameters; (2) once the ...  
WO/2021/202986A1
The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors,...  
WO/2021/175123A1
Disclosed are a 1,4-naphthoquinone compound for resisting novel coronavirus and the medical use thereof. The structure of the compound is as shown in formula (X): (X), wherein R1 is hydrogen, hydroxy, methoxy, ethoxy, benzyloxy, acetylox...  
WO/2021/173658A1
The present disclosure provides compounds of formula 1 to inhibit or prevent mitochondrial dysfunction by augmenting mitochondrial function. Mitochondrial dysfunction is the hallmark of a wide range of diseases and disorders. Mitochondri...  

Matches 1 - 50 out of 1,745